Mesoblast (MESO) Non-Current Deferred Tax Liability (2015 - 2021)
Mesoblast's (MESO) quarterly Non-Current Deferred Tax Liability came in at $80.2 million in Q2 2021, up 10881.37% year-on-year from N/an in Q2 2020, and up 10881.37% quarter-over-quarter from $730000.0 in Q2 2020.
Mesoblast (MESO) Non-Current Deferred Tax Liability (2015 - 2021) Analysis & Trends
Mesoblast has disclosed Non-Current Deferred Tax Liability across 7 years of filings, most recently posting $80.2 million for Q2 2021.
- Non-Current Deferred Tax Liability for Q2 2021 came in at $80.2 million, up 10881.37% year-over-year; the trailing twelve-month figure through Jun 2021 was $80.2 million (up 10881.37% YoY), and the FY2021 annual result was $80.2 million, up 10881.37% from the prior year.
- Non-Current Deferred Tax Liability came in at $80.2 million for Q2 2021 at Mesoblast, up from $730000.0 in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $80.2 million in Q2 2021 to a low of $730000.0 in Q2 2020.
- The 5-year median for Non-Current Deferred Tax Liability is $20.1 million (2018), against an average of $29.5 million.
- Across the five-year window, Non-Current Deferred Tax Liability plunged 99.05% in 2020 and jumped 10881.37% in 2021, its largest moves.
- Mesoblast's Non-Current Deferred Tax Liability stood at $23.9 million in 2017, then tumbled by 30.98% to $16.5 million in 2018, then plunged by 58.06% to $6.9 million in 2019, then slumped by 89.45% to $730000.0 in 2020, then surged by 10881.37% to $80.2 million in 2021.
- The last three Non-Current Deferred Tax Liability figures came in at $80.2 million (Q2 2021), $730000.0 (Q2 2020), and $5.0 million (Q1 2020), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - |
| 10 | Mesoblast | 21.68 Bn | 21.55 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2021 | 80.16 Mn |
| Jun 30, 2021 | 80.16 Mn |
| Jun 30, 2020 | 730,000.00 |
| Jun 30, 2020 | 730,000.00 |
| Mar 31, 2020 | 4.97 Mn |
| Mar 31, 2020 | 4.97 Mn |
| Dec 31, 2019 | 6.92 Mn |
| Dec 31, 2019 | 6.92 Mn |
| Sep 30, 2019 | 9.20 Mn |
| Sep 30, 2019 | 9.20 Mn |
| Jun 30, 2019 | 76.55 Mn |
| Jun 30, 2019 | 76.55 Mn |
| Mar 31, 2019 | 14.30 Mn |
| Mar 31, 2019 | 14.30 Mn |
| Dec 31, 2018 | 16.50 Mn |
| Dec 31, 2018 | 16.50 Mn |
| Sep 30, 2018 | 19.37 Mn |
| Sep 30, 2018 | 19.37 Mn |
| Jun 30, 2018 | 20.08 Mn |
| Jun 30, 2018 | 20.08 Mn |